Quarterly Financial Report: U.S. Corporations: Pharmaceuticals and Medicines: Total Current Liabilities
QFRTCL385USNO • Economic Data from Federal Reserve Economic Data (FRED)
Latest Value
403,662.00
Year-over-Year Change
25.43%
Date Range
10/1/2000 - 4/1/2025
Summary
This economic indicator tracks the total current liabilities for U.S. pharmaceutical and medicine corporations on a quarterly basis. It provides critical insight into the short-term financial obligations and financial health of a key sector in the American economy.
Analysis & Context
This economic indicator provides valuable insights into current market conditions and economic trends. The data is updated regularly by the Federal Reserve and represents one of the most reliable sources for economic analysis.
Understanding this metric helps economists, policymakers, and investors make informed decisions about economic conditions and future trends. The interactive chart above allows you to explore historical patterns and identify key trends over time.
About This Dataset
Total current liabilities represent the short-term financial obligations that pharmaceutical companies must pay within one year, including accounts payable, short-term debt, and accrued expenses. Economists and financial analysts use this metric to assess the sector's liquidity, financial stability, and potential investment risks.
Methodology
Data is collected through comprehensive quarterly financial reports submitted by pharmaceutical corporations to regulatory agencies, then aggregated and standardized by the U.S. Federal Reserve.
Historical Context
This trend is used by policymakers, investors, and financial analysts to evaluate the financial resilience and operational efficiency of the pharmaceutical industry.
Key Facts
- Represents quarterly short-term financial obligations for U.S. pharmaceutical corporations
- Includes accounts payable, short-term debt, and accrued expenses
- Provides critical insight into sector financial stability
FAQs
Q: What does total current liabilities indicate?
A: Total current liabilities show a company's short-term financial obligations due within one year. It helps assess the financial health and liquidity of pharmaceutical corporations.
Q: Why are current liabilities important for pharmaceutical companies?
A: Current liabilities reveal a company's ability to meet short-term financial commitments and provide insight into its operational efficiency and financial management.
Q: How often is this data updated?
A: The data is typically updated quarterly, reflecting the most recent financial reporting period for pharmaceutical corporations.
Q: How do investors use this information?
A: Investors analyze current liabilities to assess financial risk, evaluate company performance, and make informed investment decisions in the pharmaceutical sector.
Q: What are the limitations of this data?
A: The data represents aggregate sector information and may not capture individual company nuances or specific financial complexities.
Related Trends
Contributions to the Chicago Fed Relative Midwest Economy Index: Indiana Contribution: Consumer Spending Sector
RCONSUINM683SFRBCHI
Quarterly Financial Report: U.S. Corporations: All Manufacturing: Total Current Liabilities
QFRTCLMFGUSNO
Quarterly Financial Report: U.S. Corporations: Computer and Electronic Products: Long-Term Debt, Due in More Than 1 Year: Other Long-Term Loans
QFRD319COMUSNO
Quarterly Financial Report: U.S. Corporations: Miscellaneous Manufacturing: Short-Term Debt, Original Maturity of 1 Year or Less: Other Short-Term Loans, Including Commercial Paper
QFRD304339USNO
Quarterly Financial Report: U.S. Corporations: Computer Systems Design and Related Services: Long-Term Debt, Due in More Than 1 Year: Loans from Banks
QFR316545USNO
Quarterly Financial Report: U.S. Corporations: All Retail Trade: Total Current Assets
QFRTCARETUSNO
Citation
U.S. Federal Reserve, Quarterly Financial Report: U.S. Corporations: Pharmaceuticals and Medicines: Total Current Liabilities [QFRTCL385USNO], retrieved from FRED.
Last Checked: 8/1/2025